

Paulus Kirchhof

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3296251/publications.pdf>

Version: 2024-02-01

553
papers

166,775
citations

993

114
h-index

48

397
g-index

647
all docs

647
docs citations

647
times ranked

91689
citing authors

#	ARTICLE	IF	CITATIONS
1	2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 2016, 37, 267-315.	1.0	5,890
2	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal, 2016, 37, 2893-2962.	1.0	5,689
3	2013 ESH/ESC Guidelines for the management of arterial hypertension. European Heart Journal, 2013, 34, 2159-2219.	1.0	5,681
4	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 2021, 42, 373-498.	1.0	5,583
5	2016 European Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal, 2016, 37, 2315-2381.	1.0	5,370
6	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2016, 18, 891-975.	2.9	5,272
7	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention and Rehabilitation (EACPR). European Heart Journal, 2012, 33, 1635-1701.	1.0	5,247
8	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Heart Journal, 2012, 33, 1787-1847.	1.0	5,233
9	2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal, 2016, 37, 67-119.	1.0	5,074
10	ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal, 2012, 33, 2569-2619.	1.0	5,034
11	Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). European Heart Journal, 2010, 31, 2369-2429.	1.0	4,635
12	2013 ESH/ESC Guidelines for the management of arterial hypertension. Journal of Hypertension, 2013, 31, 1281-1357.	0.3	4,251
13	2014 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal, 2014, 35, 2541-2619.	1.0	4,141
14	2013 ESC guidelines on the management of stable coronary artery disease. European Heart Journal, 2013, 34, 2949-3003.	1.0	3,915
15	2015 ESC Guidelines for the management of infective endocarditis. European Heart Journal, 2015, 36, 3075-3128.	1.0	3,902
16	2014 ESC Guidelines on the diagnosis and treatment of aortic diseases. European Heart Journal, 2014, 35, 2873-2926.	1.0	3,549
17	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace, 2016, 18, 1609-1678.	0.7	3,523
18	2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. European Heart Journal, 2014, 35, 2733-2779.	1.0	3,469

#	ARTICLE	IF	CITATIONS
19	Guidelines on the management of valvular heart disease (version 2012). <i>European Heart Journal</i> , 2012, 33, 2451-2496.	1.0	3,465
20	2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. <i>European Heart Journal</i> , 2015, 36, 2793-2867.	1.0	3,187
21	2012 focused update of the ESC Guidelines for the management of atrial fibrillation. <i>European Heart Journal</i> , 2012, 33, 2719-2747.	1.0	3,144
22	Third Universal Definition of Myocardial Infarction. <i>Circulation</i> , 2012, 126, 2020-2035.	1.6	2,722
23	2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. <i>European Heart Journal</i> , 2014, 35, 3033-3080.	1.0	2,591
24	Third Universal Definition of Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1581-1598.	1.2	2,558
25	Third universal definition of myocardial infarction. <i>European Heart Journal</i> , 2012, 33, 2551-2567.	1.0	2,447
26	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. <i>European Heart Journal</i> , 2016, 37, 2999-3058.	1.0	2,393
27	2012 focused update of the ESC Guidelines for the management of atrial fibrillation. <i>Europace</i> , 2012, 14, 1385-1413.	0.7	2,319
28	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. <i>European Journal of Heart Failure</i> , 2012, 14, 803-869.	2.9	2,307
29	2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. <i>European Heart Journal</i> , 2013, 34, 2281-2329.	1.0	2,176
30	2014 ESC/EACTS Guidelines on myocardial revascularization. <i>European Journal of Cardio-thoracic Surgery</i> , 2014, 46, 517-592.	0.6	2,164
31	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. <i>European Heart Journal</i> , 2016, 37, 2768-2801.	1.0	1,996
32	2015 ESC Guidelines for the diagnosis and management of pericardial diseases. <i>European Heart Journal</i> , 2015, 36, 2921-2964.	1.0	1,768
33	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2013, 34, 3035-3087.	1.0	1,758
34	2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and Follow-up, Definitions, Endpoints, and Research Trial Design. <i>Heart Rhythm</i> , 2012, 9, 632-696.e21.	0.3	1,541
35	Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and Follow-up, Definitions, Endpoints, and Research Trial Design: A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the <i>E. Europace</i> , 2012, 14, 528-606.	0.7	1,497
36	Guidelines for the management of atrial fibrillation. <i>Europace</i> , 2010, 12, 1360-1420.	0.7	1,360

#	ARTICLE	IF	CITATIONS
37	Guidelines on the management of valvular heart disease (version 2012). European Journal of Cardio-thoracic Surgery, 2012, 42, S1-S44.	0.6	1,313
38	2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management. European Heart Journal, 2014, 35, 2383-2431.	1.0	1,253
39	2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Journal of Interventional Cardiac Electrophysiology, 2012, 33, 171-257.	0.6	1,167
40	Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. New England Journal of Medicine, 2020, 383, 1305-1316.	13.9	1,071
41	Pathophysiological Mechanisms of Atrial Fibrillation: A Translational Appraisal. Physiological Reviews, 2011, 91, 265-325.	13.1	1,048
42	Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace, 2015, 17, 1467-1507.	0.7	951
43	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. European Journal of Heart Failure, 2017, 19, 9-42.	2.9	920
44	Atrial fibrillation management: a prospective survey in ESC Member Countries. European Heart Journal, 2005, 26, 2422-2434.	1.0	770
45	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Journal of Cardio-thoracic Surgery, 2016, 50, e1-e88.	0.6	754
46	European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace, 2013, 15, 625-651.	0.7	721
47	2016 European Guidelines on cardiovascular disease prevention in clinical practice. European Journal of Preventive Cardiology, 2016, 23, NP1-NP96.	0.8	683
48	Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases. JAMA Cardiology, 2020, 5, 1281.	3.0	644
49	2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Europace, 2015, 17, euv319.	0.7	635
50	2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Pressure, 2014, 23, 3-16.	0.7	565
51	Multi-ethnic genome-wide association study for atrial fibrillation. Nature Genetics, 2018, 50, 1225-1233.	9.4	552
52	Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Europace, 2013, 15, 1389-1406.	0.7	494
53	Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm So. European Heart Journal, 2014, 35, 3155-3179.	1.0	490
54	Efficacy of β^2 blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet, The, 2014, 384, 2235-2243.	6.3	475

#	ARTICLE	IF	CITATIONS
55	Ca ²⁺ /calmodulin-dependent protein kinase II regulates cardiac Na ⁺ channels. <i>Journal of Clinical Investigation</i> , 2006, 116, 3127-3138.	3.9	474
56	Screening for Atrial Fibrillation. <i>Circulation</i> , 2017, 135, 1851-1867.	1.6	453
57	XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. <i>European Heart Journal</i> , 2016, 37, 1145-1153.	1.0	383
58	Age- and Training-Dependent Development of Arrhythmogenic Right Ventricular Cardiomyopathy in Heterozygous Plakoglobin-Deficient Mice. <i>Circulation</i> , 2006, 114, 1799-1806.	1.6	381
59	EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. <i>European Heart Journal</i> , 2013, 34, 2094-2106.	1.0	356
60	2013 ESH/ESC Guidelines for the management of arterial hypertension. <i>Blood Pressure</i> , 2013, 22, 193-278.	0.7	355
61	The Registry of the German Competence NETWORK on Atrial Fibrillation: patient characteristics and initial management. <i>Europace</i> , 2008, 11, 423-434.	0.7	352
62	Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention of thromboembolic events in Atrial Fibrillation (PREFER in AF). <i>Europace</i> , 2014, 16, 6-14.	0.7	349
63	Outcome parameters for trials in atrial fibrillation: executive summary: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETWORK (AFNET) and the European Heart Rhythm Association (EHRA). <i>European Heart Journal</i> , 2007, 28, 2803-2817.	1.0	335
64	Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. <i>European Heart Journal</i> , 2014, 35, 3346-3355.	1.0	329
65	Indications for the use of diagnostic implantable and external ECG loop recorders. <i>Europace</i> , 2009, 11, 671-687.	0.7	309
66	Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy. <i>European Heart Journal</i> , 2008, 29, 2125-2132.	1.0	296
67	Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention/ Stenting. <i>Thrombosis and Haemostasis</i> , 2010, 103, 13-28.	1.8	292
68	A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. <i>Europace</i> , 2014, 16, 308-319.	0.7	280
69	2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 50.	0.4	280
70	The importance of patient-reported outcomes: a call for their comprehensive integration in cardiovascular clinical trials. <i>European Heart Journal</i> , 2014, 35, 2001-2009.	1.0	274
71	Left Ventricular Unloading Is Associated With Lower Mortality in Patients With Cardiogenic Shock Treated With Venoarterial Extracorporeal Membrane Oxygenation. <i>Circulation</i> , 2020, 142, 2095-2106.	1.6	269
72	PITX2c Is Expressed in the Adult Left Atrium, and Reducing Pitx2c Expression Promotes Atrial Fibrillation Inducibility and Complex Changes in Gene Expression. <i>Circulation: Cardiovascular Genetics</i> , 2011, 4, 123-133.	5.1	267

#	ARTICLE	IF	CITATIONS
73	Outcome parameters for trials in atrial fibrillation: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. <i>Europace</i> , 2007, 9, 1006-1023.	0.7	254
74	Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. <i>BMJ</i> , The, 2015, 351, h4451.	3.0	247
75	EHRA Expert Consensus Statement on the management of cardiovascular implantable electronic devices in patients nearing end of life or requesting withdrawal of therapy. <i>Europace</i> , 2010, 12, 1480-1489.	0.7	240
76	Bleeding risk assessment and management in atrial fibrillation patients. <i>Thrombosis and Haemostasis</i> , 2011, 106, 997-1011..	1.8	234
77	EHRA/HRS/APHRS Expert Consensus on Ventricular Arrhythmias. <i>Heart Rhythm</i> , 2014, 11, e166-e196.	0.3	230
78	Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). <i>European Heart Journal</i> , 2010, 31, 1311-1318.	1.0	216
79	Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation: a randomised trial. <i>Lancet</i> , The, 2002, 360, 1275-1279.	6.3	214
80	Divergent Proarrhythmic Potential of Macrolide Antibiotics Despite Similar QT Prolongation: Fast Phase 3 Repolarization Prevents Early Afterdepolarizations and Torsade de Pointes. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 303, 218-225.	1.3	213
81	Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial. <i>American Heart Journal</i> , 2017, 190, 12-18.	1.2	209
82	Prognosis and treatment of atrial fibrillation patients by European cardiologists: One Year Follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF) Tj ETQq0 0.0gBT /Ozok 10 T	1.0	208
83	Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. <i>European Heart Journal</i> , 2017, 38, ehw058.	1.0	203
84	Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. <i>Europace</i> , 2011, 13, 723-746.	0.7	197
85	EHRA/HRS/APHRS expert consensus on ventricular arrhythmias. <i>Europace</i> , 2014, 16, 1257-1283.	0.7	194
86	Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. <i>Europace</i> , 2012, 14, 8-27.	0.7	193
87	Improved Detection of Silent Atrial Fibrillation Using 72-Hour Holter ECG in Patients With Ischemic Stroke. <i>Stroke</i> , 2013, 44, 3357-3364.	1.0	191
88	Early management of atrial fibrillation to prevent cardiovascular complications. <i>European Heart Journal</i> , 2014, 35, 1448-1456.	1.0	190
89	Searching for Atrial Fibrillation Poststroke. <i>Circulation</i> , 2019, 140, 1834-1850.	1.6	184
90	Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. <i>European Heart Journal</i> , 2018, 39, 2942-2955.	1.0	181

#	ARTICLE	IF	CITATIONS
91	Continuous Stroke Unit Electrocardiographic Monitoring Versus 24-Hour Holter Electrocardiography for Detection of Paroxysmal Atrial Fibrillation After Stroke. <i>Stroke</i> , 2012, 43, 2689-2694.	1.0	180
92	The ajmaline challenge in Brugada syndrome: Diagnostic impact, safety, and recommended protocol. <i>European Heart Journal</i> , 2003, 24, 1104-1112.	1.0	178
93	Introducing the German Mouse Clinic: open access platform for standardized phenotyping. <i>Nature Methods</i> , 2005, 2, 403-404.	9.0	176
94	Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference – research perspectives in AF™. <i>European Heart Journal</i> , 2009, 30, 2969-2980.	1.0	173
95	Brugada Syndrome and Supraventricular Tachyarrhythmias: A Novel Association?. <i>Journal of Cardiovascular Electrophysiology</i> , 2001, 12, 680-685.	0.8	161
96	The European Heart Rhythm Association symptom classification for atrial fibrillation: validation and improvement through a simple modification. <i>Europace</i> , 2014, 16, 965-972.	0.7	161
97	Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: A systematic review and meta-analysis of death and adverse outcomes. <i>International Journal of Cardiology</i> , 2016, 203, 660-666.	0.8	161
98	Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS). <i>Europace</i> , 2015, 17, 1197-1214.	0.7	160
99	ISHNE/EHRA expert consensus on remote monitoring of cardiovascular implantable electronic devices (CIEDs). <i>Europace</i> , 2012, 14, 278-293.	0.7	156
100	Familial Hypertrophic Cardiomyopathy-Linked Mutant Troponin T Causes Stress-Induced Ventricular Tachycardia and Ca ²⁺ -Dependent Action Potential Remodeling. <i>Circulation Research</i> , 2003, 92, 428-436.	2.0	151
101	Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF) Trial. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012, 5, 43-51.	2.1	147
102	Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial. <i>Lancet</i> , The, 2012, 380, 238-246.	6.3	141
103	Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub-Analysis From the PREFER in AF (Prevention of Thromboembolism and Tj ETQq1 1 0.784314 rgBT /Ov	1.6	137
104	Corrigendum to: “Guidelines for the management of atrial fibrillation” [European Heart Journal (2010) 31, 2369–2429 and EP-Europace (2010) 12, 1360–1420]. <i>European Heart Journal</i> , 2011, 32, 1172-1172.	1.0	133
105	Improving outcomes in patients with atrial fibrillation: Rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial. <i>American Heart Journal</i> , 2013, 166, 442-448.	1.2	132
106	Popeye domain containing proteins are essential for stress-mediated modulation of cardiac pacemaking in mice. <i>Journal of Clinical Investigation</i> , 2012, 122, 1119-1130.	3.9	129
107	The future of atrial fibrillation management: integrated care and stratified therapy. <i>Lancet</i> , The, 2017, 390, 1873-1887.	6.3	128
108	Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences: reasons for change to active antiarrhythmic treatment at the time of the first detected episode. <i>Europace</i> , 2007, 10, 21-27.	0.7	126

#	ARTICLE	IF	CITATIONS
109	Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial. <i>European Heart Journal</i> , 2018, 39, 2959-2971.	1.0	126
110	Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference. <i>Europace</i> , 2013, 15, 1540-1556.	0.7	125
111	Defining the major health modifiers causing atrial fibrillation: a roadmap to underpin personalized prevention and treatment. <i>Nature Reviews Cardiology</i> , 2016, 13, 230-237.	6.1	122
112	Ca/Calmodulin Kinase II Differentially Modulates Potassium Currents. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2009, 2, 285-294.	2.1	121
113	A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. <i>Europace</i> , 2016, 18, 37-50.	0.7	121
114	Prolonged Atrial Action Potential Durations and Polymorphic Atrial Tachyarrhythmias in Patients with Long QT Syndrome. <i>Journal of Cardiovascular Electrophysiology</i> , 2003, 14, 1027-1033.	0.8	119
115	Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 2497.	3.8	118
116	G-CSF/SCF reduces inducible arrhythmias in the infarcted heart potentially via increased connexin43 expression and arteriogenesis. <i>Journal of Experimental Medicine</i> , 2006, 203, 87-97.	4.2	112
117	Early Rhythm Control Therapy in Patients With Atrial Fibrillation and Heart Failure. <i>Circulation</i> , 2021, 144, 845-858.	1.6	111
118	Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. <i>European Heart Journal</i> , 2017, 38, ehw069.	1.0	106
119	Survivin Determines Cardiac Function by Controlling Total Cardiomyocyte Number. <i>Circulation</i> , 2008, 117, 1583-1593.	1.6	105
120	Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. <i>Europace</i> , 2014, 16, 1655-1673.	0.7	105
121	Early and comprehensive management of atrial fibrillation: Proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation'. <i>Europace</i> , 2009, 11, 860-885.	0.7	104
122	Gender differences in clinical presentation and 1-year outcomes in atrial fibrillation. <i>Heart</i> , 2017, 103, 1024-1030.	1.2	104
123	Giant U Waves Precede Torsades de Pointes in Long QT Syndrome. <i>Journal of the American College of Cardiology</i> , 2009, 54, 143-149.	1.2	103
124	Load-Reducing Therapy Prevents Development of Arrhythmogenic Right Ventricular Cardiomyopathy in Plakoglobin-Deficient Mice. <i>Journal of the American College of Cardiology</i> , 2011, 57, 740-750.	1.2	103
125	Catheter ablation in patients with persistent atrial fibrillation. <i>European Heart Journal</i> , 2017, 38, 20-26.	1.0	103
126	Electrophysiologic investigation in Brugada syndrome. Yield of programmed ventricular stimulation at two ventricular sites with up to three premature beats. <i>European Heart Journal</i> , 2002, 23, 1394-1401.	1.0	101

#	ARTICLE	IF	CITATIONS
127	Cardiac pacemaker function of HCN4 channels in mice is confined to embryonic development and requires cyclic AMP. <i>EMBO Journal</i> , 2008, 27, 692-703.	3.5	101
128	Management of patients with palpitations: a position paper from the European Heart Rhythm Association. <i>Europace</i> , 2011, 13, 920-934.	0.7	99
129	Management of atrial high-rate episodes detected by cardiac implanted electronic devices. <i>Nature Reviews Cardiology</i> , 2017, 14, 701-714.	6.1	98
130	European Society of Cardiology smartphone and tablet applications for patients with atrial fibrillation and their health care providers. <i>Europace</i> , 2018, 20, 225-233.	0.7	97
131	Differences among western European countries in anticoagulation management of atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2014, 112, 833-841.	1.8	96
132	Data-driven discovery and validation of circulating blood-based biomarkers associated with prevalent atrial fibrillation. <i>European Heart Journal</i> , 2019, 40, 1268-1276.	1.0	96
133	Effect of age and sex on efficacy and tolerability of β^2 blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis. <i>BMJ, The</i> , 2016, 353, i1855.	3.0	95
134	Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference. <i>Europace</i> , 2018, 20, 395-407.	0.7	95
135	Arrhythmogenic Right Ventricular Cardiomyopathy. <i>Herz</i> , 2005, 30, 91-101.	0.4	93
136	Postrepolarization Refractoriness Versus Conduction Slowing Caused by Class I Antiarrhythmic Drugs. <i>Circulation</i> , 1998, 97, 2567-2574.	1.6	91
137	PITX2 Modulates Atrial Membrane Potential and the Antiarrhythmic Effects of Sodium-Channel Blockers. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1881-1894.	1.2	90
138	Quality of life in patients with atrial fibrillation: how to assess it and how to improve it. <i>Europace</i> , 2014, 16, 787-796.	0.7	89
139	Dynamic regulation of MEK/Erks and Akt/GSK-3 β in human end-stage heart failure after left ventricular mechanical support: myocardial mechanotransduction-sensitivity as a possible molecular mechanism. <i>Cardiovascular Research</i> , 2003, 59, 390-399.	1.8	87
140	Management of atrial fibrillation by primary care physicians in Germany: baseline results of the ATRIUM registry. <i>Clinical Research in Cardiology</i> , 2011, 100, 897-905.	1.5	87
141	Health technology assessment in interventional electrophysiology and device therapy: a position paper of the European Heart Rhythm Association. <i>European Heart Journal</i> , 2013, 34, 1869-1874.	1.0	85
142	One-Year Outcome of Patients With Atrial Fibrillation Undergoing Coronary Artery Stenting: An Analysis of the AFCAS Registry. <i>Clinical Cardiology</i> , 2014, 37, 357-364.	0.7	85
143	Arrhythmogenic left atrial cellular electrophysiology in a murine genetic long QT syndrome model. <i>Cardiovascular Research</i> , 2011, 92, 67-74.	1.8	84
144	Atrial high-rate episodes and stroke prevention. <i>Europace</i> , 2017, 19, 169-179.	0.7	84

#	ARTICLE	IF	CITATIONS
145	Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial. <i>European Heart Journal</i> , 2022, 43, 1219-1230.	1.0	84
146	Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options. <i>Thrombosis and Haemostasis</i> , 2011, 106, 1012-1019..	1.8	81
147	The continuum of personalized cardiovascular medicine: a position paper of the European Society of Cardiology. <i>European Heart Journal</i> , 2014, 35, 3250-3257.	1.0	81
148	Constitutively active phosphatase inhibitor-1 improves cardiac contractility in young mice but is deleterious after catecholaminergic stress and with aging. <i>Journal of Clinical Investigation</i> , 2010, 120, 617-26.	3.9	80
149	Systematic Analysis of Gene Expression Differences between Left and Right Atria in Different Mouse Strains and in Human Atrial Tissue. <i>PLoS ONE</i> , 2011, 6, e26389.	1.1	80
150	Heart-directed Expression of a Human Cardiac Isoform of cAMP-Response Element Modulator in Transgenic Mice. <i>Journal of Biological Chemistry</i> , 2005, 280, 6906-6914.	1.6	79
151	Venice Chart International Consensus Document on Atrial Fibrillation Ablation: 2011 Update. <i>Journal of Cardiovascular Electrophysiology</i> , 2012, 23, 890-923.	0.8	79
152	'European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)' The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited) <i>Tj ETQq0 0 Q rgBT /Overlock 10 T</i> Prevention & Rehabilitation (EACPR). [<i>Eur Heart J</i> 2012;33:1635-1701, doi: 10.1093/eurheartj/ehs092]. <i>European Heart Journal</i> , 2012, 33, 2126-2126.	1.8	79
153	Detection of Asymptomatic Cerebral Microbleeds. <i>Academic Radiology</i> , 2008, 15, 895-900.	1.3	78
154	Effect of pacing and mexiletine on dispersion of repolarisation and arrhythmias in $\hat{I}''KPQ$ SCN5A (long) <i>Tj ETQq0 0 Q rgBT /Overlock 10 T</i>	1.8	77
155	Prolonged action potential durations, increased dispersion of repolarization, and polymorphic ventricular tachycardia in a mouse model of proarrhythmia. <i>Basic Research in Cardiology</i> , 2003, 98, 25-32.	2.5	76
156	A trial of self-adhesive patch electrodes and hand-held paddle electrodes for external cardioversion of atrial fibrillation (MOBIPAPA). <i>European Heart Journal</i> , 2005, 26, 1292-1297.	1.0	76
157	Universal Cardiac Induction of Human Pluripotent Stem Cells in Two and Three-Dimensional Formats: Implications for In Vitro Maturation. <i>Stem Cells</i> , 2015, 33, 1456-1469.	1.4	76
158	Myocardial Vulnerability to T Wave Shocks: Relation to Shock Strength, Shock Coupling Interval, and Dispersion of Ventricular Repolarization. <i>Journal of Cardiovascular Electrophysiology</i> , 1996, 7, 231-242.	0.8	72
159	Predicting recurrent atrial fibrillation after catheter ablation: a systematic review of prognostic models. <i>Europace</i> , 2020, 22, 748-760.	0.7	72
160	Impact of the type of centre on management of AF patients: Surprising evidence for differences in antithrombotic therapy decisions. <i>Thrombosis and Haemostasis</i> , 2011, 105, 1010-1023.	1.8	69
161	An Introduction to Murine Models of Atrial Fibrillation. <i>Frontiers in Physiology</i> , 2012, 3, 296.	1.3	69
162	Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. <i>European Heart Journal</i> , 2016, 38, ehv643.	1.0	69

#	ARTICLE	IF	CITATIONS
163	Temporal trends in incidence, causes, use of mechanical circulatory support and mortality in cardiogenic shock. <i>ESC Heart Failure</i> , 2021, 8, 1295-1303.	1.4	69
164	Prospective, multicentre validation of a simple, patient-operated electrocardiographic system for the detection of arrhythmias and electrocardiographic changes. <i>Europace</i> , 2009, 11, 1362-1368.	0.7	67
165	Insulin-Requiring Versus Noninsulin-Requiring Diabetes and Thromboembolic Risk in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2017, 69, 409-419.	1.2	67
166	Atrial Arrhythmias in Long-QT Syndrome under Daily Life Conditions: A Nested Case Control Study. <i>Journal of Cardiovascular Electrophysiology</i> , 2009, 20, 401-407.	0.8	65
167	Autonomic modulation and antiarrhythmic therapy in a model of long QT syndrome type 3. <i>Cardiovascular Research</i> , 2010, 87, 60-72.	1.8	65
168	Left Atrial Catheter Ablation and Ischemic Stroke. <i>Stroke</i> , 2012, 43, 265-270.	1.0	65
169	Atrial Fibrillation and Dementia: A Report From the AF-SCREEN International Collaboration. <i>Circulation</i> , 2022, 145, 392-409.	1.6	65
170	Prevalence of unknown atrial fibrillation in patients with risk factors. <i>Europace</i> , 2013, 15, 657-662.	0.7	64
171	ElectroMap: High-throughput open-source software for analysis and mapping of cardiac electrophysiology. <i>Scientific Reports</i> , 2019, 9, 1389.	1.6	64
172	Body Surface Area of ST Elevation and the Presence of Late Potentials Correlate to the Inducibility of Ventricular Tachyarrhythmias in Brugada Syndrome. <i>Journal of Cardiovascular Electrophysiology</i> , 2002, 13, 742-749.	0.8	63
173	The Increasing Role of Rhythm Control in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1932-1948.	1.2	63
174	Atrial fibrillation guidelines across the Atlantic: a comparison of the current recommendations of the European Society of Cardiology/European Heart Rhythm Association/European Association of Cardiothoracic Surgeons, the American College of Cardiology Foundation/American Heart Association/Heart Rhythm Society, and the Canadian Cardiovascular Society. <i>European Heart Journal</i> , 2013, 34, 1471-1474.	1.0	62
175	New devices in heart failure: an European Heart Rhythm Association report: Developed by the European Heart Rhythm Association; Endorsed by the Heart Failure Association. <i>Europace</i> , 2014, 16, 109-128.	0.7	62
176	Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology. <i>European Heart Journal</i> , 2016, 37, 747-754.	1.0	62
177	Endocardial Mapping of Right Ventricular Outflow Tract Tachycardia Using Noncontact Activation Mapping. <i>Journal of Cardiovascular Electrophysiology</i> , 2003, 14, 602-608.	0.8	60
178	Amiodarone-Induced Postrepolarization Refractoriness Suppresses Induction of Ventricular Fibrillation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 305, 257-263.	1.3	60
179	Cabins, castles, and constant hearts: rhythm control therapy in patients with atrial fibrillation. <i>European Heart Journal</i> , 2019, 40, 3793-3799c.	1.0	60
180	Cardioversion of atrial fibrillation and atrial flutter revisited: current evidence and practical guidance for a common procedure. <i>Europace</i> , 2020, 22, 1149-1161.	0.7	58

#	ARTICLE	IF	CITATIONS
181	Electro-anatomic mapping systems in arrhythmias. <i>Europace</i> , 2008, 10, iii28-iii34.	0.7	57
182	Overexpression of cAMP-response element modulator causes abnormal growth and development of the atrial myocardium resulting in a substrate for sustained atrial fibrillation in mice. <i>International Journal of Cardiology</i> , 2013, 166, 366-374.	0.8	57
183	Wolff-Parkinson-White Syndrome Associated with Brugada Syndrome. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2001, 24, 1423-1424.	0.5	56
184	Routine data from hospital information systems can support patient recruitment for clinical studies. <i>Clinical Trials</i> , 2010, 7, 183-189.	0.7	56
185	An update on atrial fibrillation in 2014: From pathophysiology to treatment. <i>International Journal of Cardiology</i> , 2016, 203, 22-29.	0.8	56
186	Electrocardiographic risk stratification in families with congenital long QT syndrome. <i>European Heart Journal</i> , 2006, 27, 2074-2080.	1.0	55
187	Rationale and current perspective for early rhythm control therapy in atrial fibrillation. <i>Europace</i> , 2011, 13, 1517-1525.	0.7	55
188	Expert opinion paper on atrial fibrillation detection after ischemic stroke. <i>Clinical Research in Cardiology</i> , 2018, 107, 871-880.	1.5	55
189	Ventricular arrhythmias, increased cardiac calmodulin kinase II expression, and altered repolarization kinetics in ANP receptor deficient mice. <i>Journal of Molecular and Cellular Cardiology</i> , 2004, 36, 691-700.	0.9	54
190	<i>PITX2</i> dependent gene regulation in atrial fibrillation and rhythm control. <i>Journal of Physiology</i> , 2017, 595, 4019-4026.	1.3	54
191	Altered sinus nodal and atrioventricular nodal function in freely moving mice overexpressing the A ₁ adenosine receptor. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2003, 285, H145-H153.	1.5	53
192	Spontaneous Brugada electrocardiogram patterns are rare in the German general population: results from the KORA study. <i>Europace</i> , 2009, 11, 1338-1344.	0.7	52
193	Systematic monitoring for detection of atrial fibrillation in patients with acute ischaemic stroke (MonDAFIS): a randomised, open-label, multicentre study. <i>Lancet Neurology</i> , The, 2021, 20, 426-436.	4.9	51
194	Knock-in gain-of-function sodium channel mutation prolongs atrial action potentials and alters atrial vulnerability. <i>Heart Rhythm</i> , 2010, 7, 1862-1869.	0.3	50
195	The Optimal Anti-Coagulation for Enhanced-Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) trial. <i>American Heart Journal</i> , 2018, 197, 124-132.	1.2	50
196	Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention of thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF). <i>BMJ Open</i> , 2019, 9, e022478.	0.8	50
197	Effects of Thoracic Epidural Anesthesia with and without Autonomic Nervous System Blockade on Cardiac Monophasic Action Potentials and Effective Refractoriness in Awake Dogs. <i>Anesthesiology</i> , 2001, 95, 132-138.	1.3	49
198	2015 ESC Guidelines for the Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 176.	0.4	48

#	ARTICLE	IF	CITATIONS
199	Global Prospective Safety Analysis ofÂRivaroxaban. Journal of the American College of Cardiology, 2018, 72, 141-153.	1.2	48
200	Net Clinical Benefit of Non-Vitamin K Antagonist vs Vitamin K Antagonist Anticoagulants in Elderly Patients with Atrial Fibrillation. American Journal of Medicine, 2019, 132, 749-757.e5.	0.6	48
201	Epigenetic and Transcriptional Networks Underlying Atrial Fibrillation. Circulation Research, 2020, 127, 34-50.	2.0	48
202	A proposal for new clinical concepts in the management of atrial fibrillation. American Heart Journal, 2012, 164, 292-302.e1.	1.2	47
203	Computer Analysis of Monophasic Action Potentials: Manual Validation and Clinically Pertinent Applications. PACE - Pacing and Clinical Electrophysiology, 1995, 18, 1666-1678.	0.5	46
204	Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. European Heart Journal: Acute Cardiovascular Care, 2015, 4, 386-386.	0.4	46
205	Depression in paroxysmal and persistent atrial fibrillation patients: a cross-sectional comparison of patients enrolled in two large clinical trialsâ€€. Europace, 2014, 16, 812-819.	0.7	45
206	Depressed mood amplifies heart-related symptoms in persistent and paroxysmal atrial fibrillation patients: a longitudinal analysisâ€”data from the German Competence Network on Atrial Fibrillation. Europace, 2015, 17, 1354-1362.	0.7	45
207	Atrial high-rate episodes: prevalence, stroke risk, implications for management, and clinical gaps in evidence. Europace, 2019, 21, 1459-1467.	0.7	45
208	Influence of age and shock severity on short-term survival in patients with cardiogenic shock. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 604-612.	0.4	45
209	Gene dose-dependent atrial arrhythmias, heart block, and brady-cardiomyopathy in mice overexpressing A3 adenosine receptors. Cardiovascular Research, 2004, 62, 500-508.	1.8	44
210	Cardiac overexpression of the human 5-HT₄receptor in mice. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 299, H788-H798.	1.5	44
211	Development and validation of a score to detect paroxysmal atrial fibrillation after stroke. Neurology, 2019, 92, e115-e124.	1.5	44
212	Reduced left atrial cardiomyocyte PITX2 and elevated circulating BMP10 predict atrial fibrillation after ablation. JCI Insight, 2020, 5, .	2.3	44
213	Ivabradine in patients with inappropriate sinus tachycardia. Naunyn-Schmiedeberg's Archives of Pharmacology, 2010, 382, 483-486.	1.4	42
214	Cardiac SARS-CoV-2 infection is associated with pro-inflammatory transcriptomic alterations within the heart. Cardiovascular Research, 2022, 118, 542-555.	1.8	42
215	Disturbed lipid and amino acid metabolisms in COVID-19 patients. Journal of Molecular Medicine, 2022, 100, 555-568.	1.7	42
216	Insights into sick sinus syndrome from an inducible mouse model. Cardiovascular Research, 2011, 90, 38-48.	1.8	39

#	ARTICLE	IF	CITATIONS
217	Proarrhythmia in a non-failing murine model of cardiac-specific Na ⁺ /Ca ²⁺ exchanger overexpression: whole heart and cellular mechanisms. <i>Basic Research in Cardiology</i> , 2012, 107, 247.	2.5	39
218	Contemporary Management of Atrial Fibrillation: What Can Clinical Registries Tell Us About Stroke Prevention and Current Therapeutic Approaches?. <i>Journal of the American Heart Association</i> , 2014, 3, .	1.6	39
219	Ventricular HCN channels decrease the repolarization reserve in the hypertrophic heart. <i>Cardiovascular Research</i> , 2012, 95, 317-326.	1.8	38
220	â€œTen Commandmentsâ€™ of 2016 ESC Guidelines for the management of atrial fibrillation. <i>European Heart Journal</i> , 2016, 37, 2853-2853.	1.0	38
221	Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: The PREFER in AF - HF substudy. <i>International Journal of Cardiology</i> , 2018, 265, 141-147.	0.8	38
222	Cardiac Optogenetics and Optical Mapping â€œ Overcoming Spectral Congestion in All-Optical Cardiac Electrophysiology. <i>Frontiers in Physiology</i> , 2019, 10, 182.	1.3	38
223	ESC Core Curriculum for the Cardiologist. <i>European Heart Journal</i> , 2020, 41, 3605-3692.	1.0	38
224	Dynamic risk assessment to improve quality of care in patients with atrial fibrillation: the 7th AFNET/EHRA Consensus Conference. <i>Europace</i> , 2021, 23, 329-344.	0.7	38
225	A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial. <i>BMJ Open</i> , 2017, 7, e015099.	0.8	37
226	A novel nonfluoroscopic catheter visualization system (Localisa) to reduce radiation exposure during catheter ablation of supraventricular tachycardias. <i>American Journal of Cardiology</i> , 2002, 90, 340-343.	0.7	36
227	Regional, age-dependent, and genotype-dependent differences in ventricular action potential duration and activation time in 410 Langendorff-perfused mouse hearts. <i>Basic Research in Cardiology</i> , 2009, 104, 523-533.	2.5	35
228	Impact of standardized MONitoring for Detection of Atrial Fibrillation in Ischemic Stroke (MonDAFIS): Rationale and design of a prospective randomized multicenter study. <i>American Heart Journal</i> , 2016, 172, 19-25.	1.2	35
229	Modification of Stretch-Induced Shortening of Repolarization by Streptomycin in the Isolated Rabbit Heart. <i>Journal of Cardiovascular Pharmacology</i> , 2000, 36, 711-721.	0.8	35
230	Morbidity and treatment in patients with atrial fibrillation and chronic kidney disease. <i>Kidney International</i> , 2015, 87, 200-209.	2.6	34
231	Design and rationale of a randomised controlled trial comparing apixaban to phenprocoumon in patients with atrial fibrillation on chronic haemodialysis: the AXADIA-AFNET 8 study. <i>BMJ Open</i> , 2018, 8, e022690.	0.8	34
232	Presenting Pattern of Atrial Fibrillation and Outcomes of Early Rhythm Control Therapy. <i>Journal of the American College of Cardiology</i> , 2022, 80, 283-295.	1.2	34
233	Healthcare personnel resource burden related to in-clinic follow-up of cardiovascular implantable electronic devices: a European Heart Rhythm Association and Eucomed joint survey. <i>Europace</i> , 2011, 13, 1166-1173.	0.7	33
234	Impact of Switching From a Vitamin K Antagonist to Rivaroxaban on Satisfaction With Anticoagulation Therapy: The XANTUSâ€™ACTS Substudy. <i>Clinical Cardiology</i> , 2016, 39, 565-569.	0.7	33

#	ARTICLE	IF	CITATIONS
235	Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, f30-f39.	1.4	33
236	Reduced Arrhythmogenicity of Biphasic Versus Monophasic T-Wave Shocks. <i>Circulation</i> , 1996, 94, 1974-1980.	1.6	33
237	Load-induced changes in repolarization: evidence from experimental and clinical data. <i>Basic Research in Cardiology</i> , 2001, 96, 369-380.	2.5	32
238	Brain MRI to personalise atrial fibrillation therapy: current evidence and perspectives. <i>Heart</i> , 2014, 100, 1408-1413.	1.2	32
239	Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial. <i>American Heart Journal</i> , 2016, 179, 59-68.	1.2	32
240	Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation. <i>Europace</i> , 2017, 19, 132-138.	0.7	32
241	Phenotyping of Mice with Heart Specific Overexpression of A2A-Adenosine Receptors: Evidence for Cardioprotective Effects of A2A-Adenosine Receptors. <i>Frontiers in Pharmacology</i> , 2018, 9, 13.	1.6	32
242	Age-dependent biochemical and contractile properties in atrium of transgenic mice overexpressing junctin. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2004, 287, H2216-H2225.	1.5	31
243	Targeted pharmacological reversal of electrical remodeling after cardioversion – Rationale and design of the Flecainide Short-Long (Flec-SL) trial. <i>American Heart Journal</i> , 2005, 150, 899.e1-899.e6.	1.2	31
244	Guía de práctica clínica de la ESC sobre diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica 2012. <i>Revista Espanola De Cardiología</i> , 2012, 65, 938.e1-938.e59.	0.6	31
245	Management of Patients With Atrial Fibrillation by Primary Care Physicians in Germany: 1-Year Results of the ATRIUM Registry. <i>Clinical Cardiology</i> , 2014, 37, 277-284.	0.7	31
246	Characteristics and outcomes of atrial fibrillation patients with or without specific symptoms: results from the PREFER in AF registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2016, 2, 299-305.	1.8	31
247	Fetoscopic Transesophageal Electrocardiography and Stimulation in Fetal Sheep. <i>Circulation</i> , 1999, 100, 772-776.	1.6	30
248	Primary prevention of sudden cardiac death. <i>Heart</i> , 2006, 92, 1873-1878.	1.2	30
249	ISHNE/EHRA Expert Consensus on Remote Monitoring of Cardiovascular Implantable Electronic Devices (CIEDs). <i>Annals of Noninvasive Electrocardiology</i> , 2012, 17, 36-56.	0.5	30
250	A Patient with "Atrial Torsades de Pointes". <i>Journal of Cardiovascular Electrophysiology</i> , 2000, 11, 806-811.	0.8	29
251	Semi-automated 3-dimensional intracardiac echocardiography: Development and initial clinical experience of a new system to guide ablation procedures. <i>Heart Rhythm</i> , 2006, 3, 1453-1459.	0.3	29
252	What are the costs of atrial fibrillation?. <i>Europace</i> , 2011, 13, ii9-ii12.	0.7	29

#	ARTICLE	IF	CITATIONS
253	XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation. <i>Vascular Health and Risk Management</i> , 2014, 10, 425.	1.0	29
254	Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe). <i>BMC Cardiovascular Disorders</i> , 2019, 19, 165.	0.7	29
255	Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 70-79.	1.4	29
256	Effects of Rivaroxaban on Biomarkers of Coagulation and Inflammation: A Post Hoc Analysis of the X-VerT Trial. <i>TH Open</i> , 2020, 04, e20-e32.	0.7	29
257	Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. <i>EuroIntervention</i> , 2015, 10, 1095-1108.	1.4	29
258	Phytanic Acid Accumulation Is Associated with Conduction Delay and Sudden Cardiac Death in Sterol Carrier Protein α 2/Sterol Carrier Protein α Deficient Mice. <i>Journal of Cardiovascular Electrophysiology</i> , 2004, 15, 1310-1316.	0.8	28
259	Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VerT trial. <i>Europace</i> , 2016, 18, 184-190.	0.7	28
260	Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban. <i>Journal of the American Heart Association</i> , 2020, 9, e009530.	1.6	28
261	Transient Local Changes in Right Ventricular Monophasic Action Potentials Due to Ajmaline in a Patient with Brugada Syndrome. <i>Journal of Cardiovascular Electrophysiology</i> , 1999, 10, 1010-1015.	0.8	27
262	Predictable and Less Predictable Unwanted Cardiac Drugs Effects: Individual PreDisposition and Transient Precipitating Factors. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2010, 106, 263-268.	1.2	27
263	Frequent and possibly inappropriate use of combination therapy with an oral anticoagulant and antiplatelet agents in patients with atrial fibrillation in Europe. <i>Heart</i> , 2014, 100, 1625-1635.	1.2	27
264	CardioPulse Articles. <i>European Heart Journal</i> , 2015, 36, 255-264.	1.0	27
265	Electrophysiological effects of flecainide and sotalol in the human atrium during persistent atrial fibrillation. <i>Basic Research in Cardiology</i> , 2005, 100, 112-121.	2.5	26
266	Real-life use of Rivaroxaban in the Netherlands: data from the Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation (XANTUS) registry. <i>Netherlands Heart Journal</i> , 2017, 25, 551-558.	0.3	26
267	Sex differences in catheter ablation of atrial fibrillation: results from AXAFA-AFNET 5. <i>Europace</i> , 2020, 22, 1026-1035.	0.7	26
268	A Regional Reduction in Ito and IKCh in the Murine Posterior Left Atrial Myocardium Is Associated with Action Potential Prolongation and Increased Ectopic Activity. <i>PLoS ONE</i> , 2016, 11, e0154077.	1.1	26
269	Early risk stratification in patients with cardiogenic shock irrespective of the underlying cause: The Cardiogenic Shock Score. <i>European Journal of Heart Failure</i> , 2022, 24, 657-667.	2.9	26
270	Diastolic isthmus length and 'vertical' isthmus angulation identify patients with difficult catheter ablation of typical atrial flutter: a pre-procedural MRI study. <i>Europace</i> , 2008, 11, 42-47.	0.7	25

#	ARTICLE	IF	CITATIONS
271	Tachycardia detection performance of implantable loop recorders: results from a large 'real-life' patient cohort and patients with induced ventricular arrhythmias. <i>Europace</i> , 2013, 15, 1215-1222.	0.7	25
272	Rationale and design of the eXplore the efficacy and safety of once-daily oral rivaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTtrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion. <i>American Heart Journal</i> , 2014, 167, 646-652.	1.2	25
273	Eligibility for mechanical circulatory support devices based on current and past randomised cardiogenic shock trials. <i>European Journal of Heart Failure</i> , 2021, 23, 1942-1951.	2.9	25
274	Hypervolemic hypertension in mice with systemic inactivation of the (floxed) guanylyl cyclase-A gene by ?MHC-Cre-mediated recombination. <i>Genesis</i> , 2004, 39, 288-298.	0.8	24
275	Inhibitor-2 prevents protein phosphatase 1-induced cardiac hypertrophy and mortality. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2008, 295, H1539-H1546.	1.5	24
276	GuÃa de prÃctica clÃnica de la ESH/ESC para el manejo de la hipertensiÃn arterial (2013). <i>Revista Espanola De Cardiologia</i> , 2013, 66, 880.e1-880.e64.	0.6	24
277	Symptom Burden of Atrial Fibrillation and Its Relation to Interventions and Outcome in Europe. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	24
278	Outcomes of anticoagulated patients with atrial fibrillation treated with or without antiplatelet therapy - A pooled analysis from the PREFER in AF and PREFER in AF PROLONGATON registries. <i>International Journal of Cardiology</i> , 2018, 270, 160-166.	0.8	24
279	Uninterrupted direct oral anticoagulants vs. uninterrupted vitamin K antagonists during catheter ablation of non-valvular atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. <i>Europace</i> , 2018, 20, 1612-1620.	0.7	24
280	Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study. <i>Journal of Cardiovascular Medicine</i> , 2019, 20, 97-104.	0.6	24
281	Stress and high heart rate provoke ventricular tachycardia in mice expressing triadin. <i>Journal of Molecular and Cellular Cardiology</i> , 2007, 42, 962-971.	0.9	23
282	Can preload-reducing therapy prevent disease progression in arrhythmogenic right ventricular cardiomyopathy? Experimental evidence and concept for a clinical trial. <i>Progress in Biophysics and Molecular Biology</i> , 2012, 110, 340-346.	1.4	23
283	Applying the ESC 2016, H₂FPEF, and HFAâ€PEFF diagnostic algorithms for heart failure with preserved ejection fraction to the general population. <i>ESC Heart Failure</i> , 2021, 8, 3603-3612.	1.4	23
284	Gender Differences in Cardiac Arrhythmias. <i>Herz</i> , 2005, 30, 390-400.	0.4	22
285	Flecainide acetate for the treatment of atrial and ventricular arrhythmias. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 347-357.	0.9	22
286	â€2012 focused update of the ESC Guidelines for the management of atrial fibrillationâ€™ [Eur Heart J (2012); 33(21):2719â€2747]. <i>European Heart Journal</i> , 2013, 34, 790-790.	1.0	22
287	An automated system using spatial oversampling for optical mapping in murine atria. Development and validation with monophasic and transmembrane action potentials. <i>Progress in Biophysics and Molecular Biology</i> , 2014, 115, 340-348.	1.4	22
288	Use of vitamin K antagonists for secondary stroke prevention depends on the treating healthcare provider in Germany â€ results from the German AFNET registry. <i>BMC Neurology</i> , 2015, 15, 129.	0.8	22

#	ARTICLE	IF	CITATIONS
289	Evidence for Arrhythmogenic Effects of A2A-Adenosine Receptors. <i>Frontiers in Pharmacology</i> , 2019, 10, 1051.	1.6	22
290	Anticoagulation, therapy of concomitant conditions, and early rhythm control therapy: a detailed analysis of treatment patterns in the EAST - AFNET 4 trial. <i>Europace</i> , 2022, 24, 552-564.	0.7	22
291	Bare-Metal vs. Drug-Eluting Stents in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>Circulation Journal</i> , 2014, 78, 2674-2681.	0.7	21
292	Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy. <i>Archives of Cardiovascular Diseases</i> , 2018, 111, 74-84.	0.7	21
293	Predictors of recurrence of atrial fibrillation within the first 3 months after ablation. <i>Europace</i> , 2020, 22, 1337-1344.	0.7	21
294	Triple antithrombotic therapy in atrial fibrillation patients with acute coronary syndromes or undergoing percutaneous coronary intervention or transcatheter aortic valve replacement. <i>EuroIntervention</i> , 2015, 10, 1015-1021.	1.4	21
295	Clinical aspects of ventricular arrhythmias associated with QT prolongation. <i>European Heart Journal Supplements</i> , 2001, 3, K81-K88.	0.0	20
296	Approach to wide complex tachycardias in patients without structural heart disease. <i>Heart</i> , 2006, 92, 704-711.	1.2	20
297	Can we improve outcomes in AF patients by early therapy?. <i>BMC Medicine</i> , 2009, 7, 72.	2.3	20
298	Spironolactone in Atrial Fibrillation With Preserved Cardiac Fraction: The IMPRESSAF Trial. <i>Journal of the American Heart Association</i> , 2020, 9, e016239.	1.6	20
299	Clinical Potential of Targeting Fibroblast Growth Factor β and \pm Klotho in the Treatment of Uremic Cardiomyopathy. <i>Journal of the American Heart Association</i> , 2020, 9, e016041.	1.6	20
300	Shock-Induced Dispersion of Ventricular Repolarization:.. <i>Journal of Cardiovascular Electrophysiology</i> , 1997, 8, 998-1008.	0.8	19
301	The management of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 82, E864-70.	0.7	19
302	Direct Oral Anticoagulants Halve Thromboembolic Events After Cardioversion of AF Compared With Warfarin. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1984-1986.	1.2	18
303	T Wave Alternans Does not Assess Arrhythmic Risk in Patients with Brugada Syndrome. <i>Annals of Noninvasive Electrocardiology</i> , 2004, 9, 162-165.	0.5	17
304	Low stroke risk after elective cardioversion of atrial fibrillation: An analysis of the Flec-SL trial. <i>International Journal of Cardiology</i> , 2013, 168, 3977-3981.	0.8	17
305	Corrigendum to: "2012 focused update of the ESC Guidelines for the management of atrial fibrillation" [Eur Heart J (2012); 33(21):2719-2747]. <i>Europace</i> , 2013, 15, 463-463.	0.7	17
306	Rate and rhythm control have comparable effects on mortality and stroke in atrial fibrillation but better data are needed. <i>Evidence-Based Medicine</i> , 2014, 19, 222-223.	0.6	17

#	ARTICLE	IF	CITATIONS
307	Bridging therapy with low molecular weight heparin in patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation: The AFCAS study. <i>International Journal of Cardiology</i> , 2015, 183, 105-110.	0.8	17
308	Cardiomyocyte functional screening: interrogating comparative electrophysiology of high-throughput model cell systems. <i>American Journal of Physiology - Cell Physiology</i> , 2019, 317, C1256-C1267.	2.1	17
309	Changes in quality of life, cognition and functional status following catheter ablation of atrial fibrillation. <i>Heart</i> , 2020, 106, 1919-1926.	1.2	17
310	Sex differences in patients with cardiogenic shock. <i>ESC Heart Failure</i> , 2021, 8, 1775-1783.	1.4	17
311	Cardiological evaluation after cerebral ischaemia. <i>Clinical Research in Cardiology</i> , 2010, 99, 609-625.	1.5	16
312	Primary Care Atrial Fibrillation Service: outcomes from consultant-led anticoagulation assessment clinics in the primary care setting in the UK. <i>BMJ Open</i> , 2015, 5, e009267.	0.8	16
313	Oral anticoagulant use in octogenarian European patients with atrial fibrillation: A subanalysis of PREFER in AF. <i>International Journal of Cardiology</i> , 2017, 232, 98-104.	0.8	16
314	Triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a viewpoint. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017, 3, 157-162.	1.4	16
315	The global Edoxaban Treatment in routine clinical practice (ETNA) noninterventional study program: rationale and design. <i>Clinical Cardiology</i> , 2019, 42, 1147-1154.	0.7	16
316	Cohort profile: the ESC EURObservational Research Programme Atrial Fibrillation III (AF III) Registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 229-237.	1.8	16
317	CMR feature tracking strain patterns and their association with circulating cardiac biomarkers in patients with hypertrophic cardiomyopathy. <i>Clinical Research in Cardiology</i> , 2021, 110, 1757-1769.	1.5	16
318	Perceived vs. objective frailty in patients with atrial fibrillation and impact on anticoagulant dosing: an ETNA-AF-Europe sub-analysis. <i>Europace</i> , 2022, 24, 1404-1411.	0.7	16
319	Bipolar ablation of therapy-refractory ventricular arrhythmias: application of a dedicated approach. <i>Europace</i> , 2022, 24, 959-969.	0.7	16
320	Minimally invasive closed-chest ultrasound-guided substance delivery into the pericardial space in mice. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2013, 386, 227-238.	1.4	15
321	Impact of anaemia on clinical outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention: insights from the AFCAS registry. <i>BMJ Open</i> , 2014, 4, e004700.	0.8	15
322	Guía de práctica clínica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes. <i>Revista Española De Cardiología</i> , 2014, 67, 136.e1-136.e56.	0.6	15
323	Effect of Concomitant Atrial Fibrillation on In-Hospital Outcomes of Non-ST-Elevation-Acute Coronary Syndrome-Related Hospitalizations in the United States. <i>American Journal of Cardiology</i> , 2019, 124, 465-475.	0.7	15
324	The Medical Profession, Industry, and Continuing Medical Education: Finding the Balance That's Right for Patients. <i>American Journal of Medicine</i> , 2019, 132, 921-925.	0.6	15

#	ARTICLE	IF	CITATIONS
325	Mortality Prediction of the CHA2DS2-VASc Score, the HAS-BLED Score, and Their Combination in Anticoagulated Patients with Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2020, 9, 3987.	1.0	15
326	Prognostic markers of all-cause mortality in patients with atrial fibrillation: data from the prospective long-term registry of the German Atrial Fibrillation NETwork (AFNET). <i>Europace</i> , 2021, 23, 1903-1912.	0.7	15
327	Association Between the Acidemia, Lactic Acidosis, and Shock Severity With Outcomes in Patients With Cardiogenic Shock. <i>Journal of the American Heart Association</i> , 2022, 11, e024932.	1.6	15
328	Torsade de pointes induced by ajmaline. <i>Clinical Research in Cardiology</i> , 2001, 90, 586-590.	1.2	14
329	Arrhythmogenic right ventricular cardiomyopathy. <i>Herzschrittmachertherapie Und Elektrophysiologie</i> , 2012, 23, 186-195.	0.3	14
330	Actualizaci3n detallada de las gu3as de la ESC para el manejo de la fibrilaci3n auricular de 2012. <i>Revista Espanola De Cardiologia</i> , 2013, 66, 54.e1-54.e24.	0.6	14
331	Gone Fishing (for Silent Atrial Fibrillation). <i>Circulation</i> , 2013, 127, 870-872.	1.6	14
332	IMproved exercise tolerance in patients with PReserved Ejection fraction by Spironolactone on myocardial fibrosiS in Atrial Fibrillation rationale and design of the IMPRESS-AF randomised controlled trial. <i>BMJ Open</i> , 2016, 6, e012241.	0.8	14
333	Integrated care of patients with atrial fibrillation: the 2016 ESC atrial fibrillation guidelines. <i>Heart</i> , 2017, 103, 729-731.	1.2	14
334	Atrial fibrillation patterns are associated with arrhythmia progression and clinical outcomes. <i>Heart</i> , 2018, 104, 1608-1614.	1.2	14
335	Digital learning and the future cardiologist. <i>European Heart Journal</i> , 2019, 40, 499-501.	1.0	14
336	Novel Wide-Band Dielectric Imaging System and Occlusion Tool to Guide Cryoballoon-Based Pulmonary Vein Isolation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e009219.	2.1	14
337	Safety and Effectiveness of Edoxaban in Atrial Fibrillation Patients in Routine Clinical Practice: One-Year Follow-Up from the Global Noninterventional ETNA-AF Program. <i>Journal of Clinical Medicine</i> , 2021, 10, 573.	1.0	14
338	A Novel miRNA Screen Identifies miRNA-4454 as a Candidate Biomarker for Ventricular Fibrosis in Patients with Hypertrophic Cardiomyopathy. <i>Biomolecules</i> , 2021, 11, 1718.	1.8	14
339	Generalizability of the EAST4 AFNET 4 Trial: Assessing Outcomes of Early Rhythm Control Therapy in Patients With Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	14
340	Eligibility for early rhythm control in patients with atrial fibrillation in the UK Biobank. <i>Heart</i> , 2022, 108, 1873-1880.	1.2	14
341	Of hammers and screws: renin-angiotensin-aldosterone system inhibition to prevent atrial fibrillation in patients with hypertension. <i>European Heart Journal</i> , 2014, 35, 1169-1171.	1.0	13
342	Outcomes after catheter ablation and cardioversion in patients with non-valvular atrial fibrillation: results from the prospective, observational XANTUS study. <i>Europace</i> , 2018, 20, e87-e95.	0.7	13

#	ARTICLE	IF	CITATIONS
343	Outcome of left atrial appendage occlusion in high-risk patients. <i>Heart</i> , 2018, 104, 594-599.	1.2	13
344	The Biomarkers NT-proBNP and CA-125 are Elevated in Patients with Idiopathic Atrial Fibrillation. <i>Journal of Atrial Fibrillation</i> , 2018, 11, 2058.	0.5	13
345	The additive prognostic value of coronary calcium score (CCS) to single photon emission computed tomography myocardial perfusion imaging (SPECT-MPI)-real world data from a single center. <i>Journal of Nuclear Cardiology</i> , 2021, 28, 2086-2096.	1.4	13
346	Effects of genetic background, sex, and age on murine atrial electrophysiology. <i>Europace</i> , 2021, 23, 958-969.	0.7	13
347	Phase angle convergence of multiple monophasic action potential recordings precedes spontaneous termination of ventricular fibrillation. <i>Basic Research in Cardiology</i> , 1998, 93, 412-421.	2.5	12
348	Clinical Value of Electrocardiographic Parameters in Genotyped Individuals with Familial Long QT Syndrome. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2001, 24, 406-415.	0.5	12
349	Prolonged QRS Duration Increases QT Dispersion But Does Not Relate to Arrhythmias in Survivors of Acute Myocardial Infarction. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2001, 24, 789-795.	0.5	12
350	Effect of Electrode Position on the Outcome of Cardioversion. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2003, 7, 292-296.	0.9	12
351	The German Competence Network on Atrial Fibrillation (AFNET). <i>Herz</i> , 2008, 33, 548-555.	0.4	12
352	Risk factors and outcome of new-onset cardiac arrhythmias in vascular surgery patients. <i>American Heart Journal</i> , 2010, 159, 1108-1115.	1.2	12
353	Regulatory pathways for development of antiarrhythmic drugs for management of atrial fibrillation/flutter. <i>Europace</i> , 2011, 13, 1063-1076.	0.7	12
354	Nitrite circumvents platelet resistance to nitric oxide in patients with heart failure preserved ejection fraction and chronic atrial fibrillation. <i>Cardiovascular Research</i> , 2018, 114, 1313-1323.	1.8	12
355	Expert opinion paper on cardiac imaging after ischemic stroke. <i>Clinical Research in Cardiology</i> , 2021, 110, 938-958.	1.5	12
356	Atrial resting membrane potential confers sodium current sensitivity to propafenone, flecainide and dronedarone. <i>Heart Rhythm</i> , 2021, 18, 1212-1220.	0.3	12
357	CMR-Based Risk Stratification of Sudden Cardiac Death and Use of Implantable Cardioverter-Defibrillator in Non-Ischemic Cardiomyopathy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7115.	1.8	12
358	Increased atrial effectiveness of flecainide conferred by altered biophysical properties of sodium channels. <i>Journal of Molecular and Cellular Cardiology</i> , 2022, 166, 23-35.	0.9	12
359	MRI-Detected Brain Lesions and Cognitive Function in Patients With Atrial Fibrillation Undergoing Left Atrial Catheter Ablation in the Randomized AXAFA-AFNET 5 Trial. <i>Circulation</i> , 2022, 145, 906-915.	1.6	12
360	Single-dose of adrenergic versus placebo in acute cardiogenic shock (ACCOST-HH): an investigator-initiated, randomised, double-blinded, placebo-controlled, multicentre trial. <i>Lancet Respiratory Medicine</i> , 2022, 10, 247-254.	5.2	12

#	ARTICLE	IF	CITATIONS
361	Incessant Supraventricular Tachycardia with Constant 1:2 Atrioventricular Ratio: Journal of Cardiovascular Electrophysiology, 2003, 14, 316-319.	0.8	11
362	Hypertension begets hypertrophy begets atrial fibrillation? Insights from yet another sheep model. European Heart Journal, 2006, 27, 2919-2920.	1.0	11
363	Stratified prevention: opportunities and limitations. Report on the 1st interdisciplinary cardiovascular workshop in Augsburg. Clinical Research in Cardiology, 2018, 107, 193-200.	1.5	11
364	The future of continuing medical education: the roles of medical professional societies and the health care industry. European Heart Journal, 2019, 40, 1720-1727.	1.0	11
365	Thromboembolic and bleeding risk in obese patients with atrial fibrillation according to different anticoagulation strategies. International Journal of Cardiology, 2020, 318, 67-73.	0.8	11
366	Quantification of fibroblast growth factor 23 and N-terminal pro-B-type natriuretic peptide to identify patients with atrial fibrillation using a high-throughput platform: A validation study. PLoS Medicine, 2021, 18, e1003405.	3.9	11
367	Genetics of atrial fibrillation—practical applications for clinical management: if not now, when and how?. Cardiovascular Research, 2021, 117, 1718-1731.	1.8	11
368	Reclassification, Thromboembolic, and Major Bleeding Outcomes Using Different Estimates of Renal Function in Anticoagulated Patients With Atrial Fibrillation: Insights From the PREFER-in-AF and PREFER-in-AF Prolongation Registries. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e006852.	0.9	11
369	Intermittent Optogenetic Tachypacing of Atrial Engineered Heart Tissue Induces Only Limited Electrical Remodelling. Journal of Cardiovascular Pharmacology, 2021, 77, 291-299.	0.8	11
370	The established and the challenger: A direct comparison of current cryoballoon technologies for pulmonary vein isolation. Journal of Cardiovascular Electrophysiology, 2022, 33, 48-54.	0.8	11
371	Interactions Between Atrial Fibrillation and Natriuretic Peptide in Predicting Heart Failure Hospitalization or Cardiovascular Death. Journal of the American Heart Association, 2022, 11, e022833.	1.6	11
372	Machine learning-based identification of risk-factor signatures for undiagnosed atrial fibrillation in primary prevention and post-stroke in clinical practice. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 9, 16-23.	1.8	11
373	Pauses after burst pacing provoke afterdepolarizations and torsades de pointes in a patient with long QT syndrome. Heart Rhythm, 2004, 1, 720-723.	0.3	10
374	New concepts for old drugs to maintain sinus rhythm in patients with atrial fibrillation. Heart Rhythm, 2007, 4, 790-793.	0.3	10
375	Novel non-pharmacological approaches for antiarrhythmic therapy of atrial fibrillation. Europace, 2008, 10, 433-437.	0.7	10
376	Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKET AF and XANTUS. Europace, 2019, 21, 421-427.	0.7	10
377	Development and external validation of predictive models for prevalent and recurrent atrial fibrillation: a protocol for the analysis of the CATCH ME combined dataset. BMC Cardiovascular Disorders, 2019, 19, 120.	0.7	10
378	Effect of Sotalol and Acute Ventricular Dilatation on Action Potential Duration and Dispersion of Repolarization After Defibrillation Shocks. Journal of Cardiovascular Pharmacology, 2003, 41, 640-648.	0.8	9

#	ARTICLE	IF	CITATIONS
379	Ectopic thyroid mass in the heart. <i>Lancet, The</i> , 2012, 379, 1762.	6.3	9
380	Recent advances in rhythm control for atrial fibrillation. <i>F1000Research</i> , 2017, 6, 1796.	0.8	9
381	ESC Apps for Atrial Fibrillation. <i>European Heart Journal</i> , 2017, 38, 2643-2645.	1.0	9
382	High-Throughput Analysis of Optical Mapping Data Using ElectroMap. <i>Journal of Visualized Experiments</i> , 2019, , .	0.2	9
383	The European Network for Translational Research in Atrial Fibrillation (EUTRAF): objectives and initial results. <i>Europace</i> , 2015, 17, 1457-1466.	0.7	8
384	Pitx2 Adjacent Noncoding RNA. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2016, 9, e003808.	2.1	8
385	MRI-detected brain lesions in AF patients without further stroke risk factors undergoing ablation - a retrospective analysis of prospective studies. <i>BMC Cardiovascular Disorders</i> , 2019, 19, 58.	0.7	8
386	Roadmap for cardiovascular education across the European Society of Cardiology: inspiring better knowledge and skills, now and for the future. <i>European Heart Journal</i> , 2019, 40, 1728-1738.	1.0	8
387	Clinical characteristics and outcomes of patients with adult congenital heart disease listed for heart and heart-lung transplantation in the Eurotransplant region. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 1238-1249.	0.3	8
388	Cytokine-Mediated Alterations of Human Cardiac Fibroblast's Secretome. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12262.	1.8	8
389	High resolution optical mapping of cardiac electrophysiology in pre-clinical models. <i>Scientific Data</i> , 2022, 9, 135.	2.4	8
390	Drugs that interact with cardiac electro-mechanics: Old and new targets for treatment. <i>Progress in Biophysics and Molecular Biology</i> , 2008, 97, 497-512.	1.4	7
391	Right Atrial Scar Detection after Catheter Ablation. <i>Academic Radiology</i> , 2011, 18, 488-494.	1.3	7
392	To the Editor: Propranolol, a β^2 -adrenoreceptor blocker, prevents arrhythmias also by its sodium channel blocking effect. <i>Heart Rhythm</i> , 2014, 11, e1.	0.3	7
393	Predictors of sinus rhythm after electrical cardioversion of atrial fibrillation: results from a data mining project on the Flec-SL trial data set. <i>Europace</i> , 2017, 19, euw144.	0.7	7
394	Which patients with atrial fibrillation undergo an ablation procedure today in Europe? A report from the ESC-EHRA-EORP Atrial Fibrillation Ablation Long-Term and Atrial Fibrillation General Pilot Registries. <i>Europace</i> , 2020, 22, 250-258.	0.7	7
395	A tale of two countries: how decentralized organization and long-term investment build resilient healthcare systems. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2020, 6, 201-203.	1.8	7
396	Automatic Holter electrocardiogram analysis in ischaemic stroke patients to detect paroxysmal atrial fibrillation: ready to replace physicians?. <i>European Journal of Neurology</i> , 2020, 27, 1272-1278.	1.7	7

#	ARTICLE	IF	CITATIONS
397	Improving the diagnosis of heart failure in patients with atrial fibrillation. <i>Heart</i> , 2021, 107, 902-908.	1.2	7
398	Impact of Weight on Clinical Outcomes of Edoxaban Therapy in Atrial Fibrillation Patients Included in the ETNA-AF-Europe Registry. <i>Journal of Clinical Medicine</i> , 2021, 10, 2879.	1.0	7
399	Coincidence of paroxysmal supraventricular tachycardia and panic disorder: two case reports. <i>Annals of General Psychiatry</i> , 2010, 9, 13.	1.2	6
400	CardioPulse Articles. <i>European Heart Journal</i> , 2012, 33, 147-156.	1.0	6
401	Anterior T-Wave Inversion Does Not Convey Short-Term Sudden Death Risk. <i>Journal of the American College of Cardiology</i> , 2017, 69, 10-12.	1.2	6
402	SMART About Watches. <i>JACC: Clinical Electrophysiology</i> , 2019, 5, 209-211.	1.3	6
403	Factors associated with the dosing of edoxaban for stroke prevention in patients with atrial fibrillation from South Korea and Taiwan: 1-year data from the Global ETNA-AF Program. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 485-490.	0.6	6
404	Induction of ventricular fibrillation by T-wave field-shocks in the isolated perfused rabbit heart: Role of nonuniform shock responses. <i>Basic Research in Cardiology</i> , 1997, 92, 35-44.	2.5	6
405	Accuracy and Acute Efficacy of the Novel Injection-Based Occlusion Algorithm in Cryoballoon Pulmonary Vein Isolation Guided by Dielectric Imaging. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2022, 15, CIRCEP121010174.	2.1	6
406	Bilateral Remote Ischaemic Conditioning in Children (BRICC) trial: protocol for a two-centre, double-blind, randomised controlled trial in young children undergoing cardiac surgery. <i>BMJ Open</i> , 2020, 10, e042176.	0.8	6
407	In vivo recording of monophasic action potentials in awake dogs - new applications for experimental electrophysiology. <i>Basic Research in Cardiology</i> , 2001, 96, 169-174.	2.5	5
408	Intracardiac Tuberculoma Causing "Idiopathic" Ventricular Tachycardia in a Patient Without Detectable Heart Disease. <i>Journal of Cardiovascular Electrophysiology</i> , 2001, 12, 118-118.	0.8	5
409	Genetic aspects in acquired long QT syndrome ? a piece in the puzzle. <i>European Heart Journal Supplements</i> , 2001, 3, K48-K52.	0.0	5
410	Ablation of atrial fibrillation: for whom and how?. <i>Heart</i> , 2010, 96, 1325-1330.	1.2	5
411	Difficult decision making in the management of patients with atrial fibrillation and acute coronary syndrome or invasive cardiovascular interventions: new recommendations for daily practice. <i>Europace</i> , 2015, 17, 1319-1322.	0.7	5
412	Oral anticoagulation after catheter ablation of atrial fibrillation: caught in the attribution trap?. <i>European Heart Journal</i> , 2015, 36, 267-269.	1.0	5
413	Temporal irregularity quantification and mapping of optical action potentials using wave morphology similarity. <i>Progress in Biophysics and Molecular Biology</i> , 2020, 157, 84-93.	1.4	5
414	Biomarkers Associated With Aortic Valve Calcification: Should We Focus on Sex Specific Processes?. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 604.	1.8	5

#	ARTICLE	IF	CITATIONS
415	Detection of unknown atrial fibrillation by prolonged ECG monitoring in an all-comer patient cohort and association with clinical and Holter variables. <i>Open Heart</i> , 2020, 7, e001151.	0.9	5
416	Heart failure in adults with congenital heart disease: a narrative review. <i>Cardiovascular Diagnosis and Therapy</i> , 2021, 11, 529-537.	0.7	5
417	Mitral Regurgitation Following Acute Myocardial Infarction Treated by Percutaneous Coronary Intervention—Prevalence, Risk factors, and Predictors of Outcome. <i>American Journal of Cardiology</i> , 2021, 157, 22-32.	0.7	5
418	Basic Research Approaches to Evaluate Cardiac Arrhythmia in Heart Failure and Beyond. <i>Frontiers in Physiology</i> , 2022, 13, 806366.	1.3	5
419	Clinical Performance of Oral Anticoagulants in Elderly with Atrial Fibrillation and Low Body Weight: Insight into Italian Cohort of PREFER-AF and PREFER-AF Prolongation Registries. <i>Journal of Clinical Medicine</i> , 2022, 11, 3751.	1.0	5
420	Simultaneous in utero assessment of AV nodal and ventricular electrophysiologic parameters in the fetal sheep heart. <i>Basic Research in Cardiology</i> , 2001, 96, 251-257.	2.5	4
421	In vivo recording of monophasic action potentials in awake dogs. <i>Methods</i> , 2003, 30, 109-114.	1.9	4
422	Guidelines for the management of atrial fibrillation. <i>Europace</i> , 2011, 13, 1058-1058.	0.7	4
423	First Report on an Inotropic Peptide Activating Tetrodotoxin-Sensitive, α -Neuronal Sodium Currents in the Heart. <i>Circulation: Heart Failure</i> , 2015, 8, 79-88.	1.6	4
424	Can biomarkers balance stroke and bleeding risk?. <i>Lancet</i> , The, 2016, 387, 2266-2268.	6.3	4
425	Is there a CASTLE-AF on the hill?. <i>European Heart Journal</i> , 2018, 39, 1324-1325.	1.0	4
426	Safety and efficacy of uninterrupted vs. minimally interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: two sides of the same coin?. <i>Europace</i> , 2019, 21, 181-183.	0.7	4
427	The National Institute for Health Research (NIHR) Global Health Research Group on Atrial Fibrillation management. <i>European Heart Journal</i> , 2019, 40, 3005-3007.	1.0	4
428	The Amplitude-Normalized Area of a Bipolar Electrogram as a Measure of Local Conduction Delay in the Heart. <i>Frontiers in Physiology</i> , 2020, 11, 465.	1.3	4
429	Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry. <i>Internal and Emergency Medicine</i> , 2021, 16, 591-599.	1.0	4
430	Outcome of pregnancy in a contemporary cohort of adults with congenital heart disease—a 10-year, single-center experience. <i>Cardiovascular Diagnosis and Therapy</i> , 2021, 11, 1344-1355.	0.7	4
431	Impact of atrial fibrillation pattern on outcomes after left atrial appendage closure: lessons from the prospective LAARGE registry. <i>Clinical Research in Cardiology</i> , 2022, 111, 511-521.	1.5	4
432	Regulation of basal and norepinephrine-induced cAMP and ICa in hiPSC-cardiomyocytes: Effects of culture conditions and comparison to adult human atrial cardiomyocytes. <i>Cellular Signalling</i> , 2021, 82, 109970.	1.7	4

#	ARTICLE	IF	CITATIONS
433	Study design and rationale of the pAtients pResenTing with cOngenital heaRt dIseAsE Register (ARTORIAâ€). ESC Heart Failure, 2021, 8, 5542-5550.	1.4	4
434	Preclinical Testing of Drug-Induced Proarrhythmia: Value of Transgenic Models. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2007, 5, 289-294.	0.4	4
435	Wytyczne ESH/ESC dotyczÄ...ce postÄ™powania w nadciÄnieniu tÄ™tnicznym w 2013 roku. Kardiologia Polska, 2013, 71, 27-118.	0.3	4
436	Atrial fibrillation, thromboembolism, and haemostasis: causal or casual associations?. Thrombosis and Haemostasis, 2003, 90, 973-975.	1.8	3
437	An ultrasound view on the substrate for incident and recurrent atrial fibrillation in heart failure patients. European Journal of Heart Failure, 2010, 12, 1019-1020.	2.9	3
438	Gene construction, expression and functional testing of an inotropic peptide from the venom of the black scorpion Hottentotta judaicus. Toxicon, 2012, 60, 1415-1427.	0.8	3
439	Selective atrial profibrotic signalling in mice and man. Cardiovascular Research, 2013, 99, 592-594.	1.8	3
440	Authors' response: From monitoring to vigilance about patient adherence to new oral anticoagulants. Europace, 2014, 16, 149-150.	0.7	3
441	EHRA/HRS/APHRS expert consensus on ventricular arrhythmias. Journal of Arrhythmia, 2014, 30, 327-349.	0.5	3
442	Almanac 2015: atrial fibrillation research in Heart. Heart, 2016, 102, 573-580.	1.2	3
443	The RACE-3 is on: double-locking sinus rhythm by upstream and downstream therapy. European Heart Journal, 2018, 39, 2997-2999.	1.0	3
444	Clinical characteristics of heart failure patients undergoing atrial fibrillation ablation today in Europe. Data from the atrial fibrillation registries of the European Society of Cardiology and the European Heart Rhythm Association. European Journal of Heart Failure, 2019, 21, 690-693.	2.9	3
445	Complex antithrombotic combinations: how to find the perfect blend?. Heart, 2020, 106, 557-558.	1.2	3
446	The RACE to the EAST. In pursuit of rhythm control therapy for atrial fibrillationâ€”a dedication to Harry Crijns. Europace, 2021, 23, ii34-ii39.	0.7	3
447	Endovascular extraction of a coronary stent: resolution of a cathlab nightmare. EuroIntervention, 2011, 7, 1008-1008.	1.4	3
448	International cohort study on the effectiveness of dronedarone and other antiarrhythmic drugs for atrial fibrillation in real-world practice (EFFECT-AF). Europace, 2022, 24, 899-909.	0.7	3
449	Mechanism of catecholamine-induced ventricular tachycardias in mice with heart-directed expression of junctin and triadin: Shortening of action potentials and prolonged calcium transients. Heart Rhythm, 2005, 2, S69.	0.3	2
450	Catheter ablation of scar-related ventricular tachycardia: Another piece of the puzzle. Heart Rhythm, 2008, 5, 375-377.	0.3	2

#	ARTICLE	IF	CITATIONS
451	Data mining for detecting disturbances in heart rhythm. , 2008, , .		2
452	MRI of Right Atrial Function after Catheter Ablation of Atrial Flutter. Academic Radiology, 2010, 17, 856-861.	1.3	2
453	Guía de práctica clínica sobre el tratamiento de las valvulopatías (versión 2012). Revista Espanola De Cardiologia, 2013, 66, 131.e1-131.e42.	0.6	2
454	Author reply. Europace, 2014, 16, 151-152.	0.7	2
455	Evolving perspectives for personalised management of patients with atrial fibrillation: Table 1. Heart, 2014, 100, 1071-1072.	1.2	2
456	Treatment Satisfaction In Patients With Atrial Fibrillation On New Oral Anticoagulants As Assessed With Pact-Q2 At Baseline And 12-Month Follow-Up: Prefer In Af Registry. Value in Health, 2014, 17, A497.	0.1	2
457	What's new in the 2016 ESC Guidelines on atrial fibrillation?. European Heart Journal, 2016, 37, 2851-2852.	1.0	2
458	Patient-centred care of patients with ventricular arrhythmias and risk of sudden cardiac death: What do the 2015 European Society of Cardiology guidelines add?. European Journal of Cardiovascular Nursing, 2017, 16, 558-564.	0.4	2
459	Training the next generation of cardiovascular leaders in health policy and economics. European Heart Journal, 2017, 38, 3332-3335.	1.0	2
460	NOACs in Atrial Fibrillation. European Heart Journal, 2017, 38, 2382-2385.	1.0	2
461	Editor's Choice- Practical challenges regarding in-hospital telemetry monitoring require the development of European practice standards. European Heart Journal: Acute Cardiovascular Care, 2018, 7, 774-776.	0.4	2
462	Prognostic models for predicting incident or recurrent atrial fibrillation: protocol for a systematic review. Systematic Reviews, 2019, 8, 221.	2.5	2
463	Second look Holter ECG in neurorehabilitation. Neurological Research and Practice, 2019, 1, 41.	1.0	2
464	Impact of gender: Rivaroxaban for patients with atrial fibrillation in the <scp>XANTUS</scp> real-world prospective study. Clinical Cardiology, 2020, 43, 1405-1413.	0.7	2
465	Integrated care in stroke survivors: When and how much?. EclinicalMedicine, 2020, 25, 100489.	3.2	2
466	Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and The Netherlands: insights from the ETNA-AF-Europe study. Acta Cardiologica, 2021, 76, 431-439.	0.3	2
467	Anticoagulation management in adult patients with congenital heart disease: a narrative review. Cardiovascular Diagnosis and Therapy, 2021, 11, 0-0.	0.7	2
468	Mobile health for walking on the tightrope of optimal physical activity to reduce the risk of atrial fibrillation. European Heart Journal, 2021, 42, 2484-2486.	1.0	2

#	ARTICLE	IF	CITATIONS
469	The European Heart Rhythm Association Practical Guide on the Use of New Oral Anticoagulants in Patients with Non-valvular Atrial Fibrillation – A Brief Summary. <i>Arrhythmia and Electrophysiology Review</i> , 2013, 2, 115.	1.3	2
470	Spironolactone to improve exercise tolerance in people with permanent atrial fibrillation and preserved ejection fraction: the IMPRESS-AF RCT. <i>Efficacy and Mechanism Evaluation</i> , 2020, 7, 1-42.	0.9	2
471	Bilateral Remote Ischaemic Conditioning in Children (BRICC) trial: protocol for a two-centre, double-blind, randomised controlled trial in young children undergoing cardiac surgery. <i>BMJ Open</i> , 2020, 10, e042176.	0.8	2
472	Clinical Events with Edoxaban in South Korean and Taiwanese Atrial Fibrillation Patients in Routine Clinical Practice. <i>Journal of Clinical Medicine</i> , 2021, 10, 5337.	1.0	2
473	Atrial fibrillation ablation in heart failure: Findings from the ESC-EHRA EORP Atrial Fibrillation Ablation long-term (AFA LT) registry. <i>International Journal of Cardiology</i> , 2022, 346, 19-26.	0.8	2
474	The Atrial Fibrillation Heart Team’s guiding therapy in left atrial appendage occlusion with increasingly complex patients and little evidence. <i>European Heart Journal</i> , 2022, 43, 1691-1692.	1.0	2
475	CA-536-01 PULSED-FIELD ABLATION BASED PULMONARY VEIN ISOLATION: ACUTE SAFETY AND EFFICACY IN A MULTI-CENTER REAL WORLD SCENARIO. <i>Heart Rhythm</i> , 2022, 19, S91.	0.3	2
476	Association of stroke lesion shape with newly detected atrial fibrillation – Results from the MonDAFIS study. <i>European Stroke Journal</i> , 2022, 7, 230-237.	2.7	2
477	Ablation of Outflow Tract Arrhythmias in Patients With and Without Structural Heart Disease – A Comparative Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, .	1.1	2
478	Cardiovert! – or better wait a little? Systematic evidence that the initial hours of atrial fibrillation are a – special time –. <i>Heart Rhythm</i> , 2005, 2, 1330-1331.	0.3	1
479	Electrocardiographic markers of sudden cardiac death. <i>Journal of Electrocardiology</i> , 2007, 40, S9-S10.	0.4	1
480	Antithrombotic therapy use for patients with atrial fibrillation undergoing percutaneous coronary intervention: new data in an area of limited evidence. <i>Europace</i> , 2009, 11, 842-843.	0.7	1
481	Corrigendum to: 'HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies' [<i>Europace</i> 2011;13:1077-109, doi: 10.1093/europace/eur245]. <i>Europace</i> , 2012, 14, 277-277.	0.7	1
482	Postrepolarization refractoriness: A mechanism in need for a molecule?. <i>Heart Rhythm</i> , 2012, 9, 983-984.	0.3	1
483	205 – ...Atrial Arrhythmia Susceptibility in Arrhythmogenic Right Ventricular Cardiomyopathy. <i>Heart</i> , 2014, 100, A112.2-A113.	1.2	1
484	Discontinuation And Hospitalisation Rates In Patients With Atrial Fibrillation: Follow-Up Results Of The Prefer In Af Registry. <i>Value in Health</i> , 2014, 17, A473.	0.1	1
485	26 – ...Digoxin – Friend or Foe? A Comprehensive Review of Digoxin use and Mortality. <i>Heart</i> , 2015, 101, A14.2-A15.	1.2	1
486	My atrial fibrillation is not your atrial fibrillation. <i>European Heart Journal</i> , 2017, 38, 2608-2611.	1.0	1

#	ARTICLE	IF	CITATIONS
487	83â€¦Use of feature tracking to assess systemic right ventricles in congenital heart disease patients with both single and dual ventricular circulations. <i>Heart</i> , 2017, 103, A60.2-A62.	1.2	1
488	Improving outcomes after catheter ablation of atrial fibrillation: better patient selection, better procedure, or both?. <i>European Heart Journal</i> , 2018, 39, 450-452.	1.0	1
489	Trusting our cardiology trainees. <i>European Heart Journal</i> , 2020, 41, 3601-3602.	1.0	1
490	Self-palpation for detection of paroxysmal atrial fibrillation: Much noise with little signal. <i>PLoS Medicine</i> , 2020, 17, e1003098.	3.9	1
491	Genetic and Clinical Predictors of Left Atrial Thrombus: A Single Center Case-Control Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110211.	0.7	1
492	Seasonal trends of incidence and outcomes of cardiogenic shock : findings from a large, nationwide inpatients sample with 441,696 cases. <i>Critical Care</i> , 2021, 25, 325.	2.5	1
493	Primary Prevention of Ischaemic Stroke in Atrial Fibrillation: New Oral Anticoagulant Drugs for all?. <i>Current Vascular Pharmacology</i> , 2014, 12, 373-383.	0.8	1
494	The characteristics of mitral regurgitation: Data from patients admitted following acute myocardial infarction. <i>Data in Brief</i> , 2021, 39, 107451.	0.5	1
495	Non-Invasive Risk Prediction Based on Right Ventricular Function in Patients with Pulmonary Arterial Hypertension. <i>Journal of Clinical Medicine</i> , 2021, 10, 5130.	1.0	1
496	In Patients With Recently Diagnosed Atrial Fibrillation, Think Anticoagulation and Rhythm Control. <i>Circulation</i> , 2021, 144, 1587-1589.	1.6	1
497	LMNA Mutation in a Family with a Strong History of Sudden Cardiac Death. <i>Genes</i> , 2022, 13, 169.	1.0	1
498	CardioPulse: New perspectives for stroke prevention in atrial fibrillation. <i>European Heart Journal</i> , 2016, 37, 583-4.	1.0	1
499	Management of pericardial tamponade in the electrophysiology laboratory: results from a national survey. <i>Clinical Research in Cardiology</i> , 2023, 112, 1727-1737.	1.5	1
500	Reproducible Conversion from Wide to Narrow Complex Tachycardia:.. <i>Journal of Cardiovascular Electrophysiology</i> , 2000, 11, 941-943.	0.8	0
501	A Monogenic Avalanche. <i>Journal of Cardiovascular Electrophysiology</i> , 2002, 13, 689-690.	0.8	0
502	Molekulare Mechanismen des plij;1/2tzlichen Herztods und ihre klinische Bedeutung. <i>Herzschrittmachertherapie Und Elektrophysiologie</i> , 2003, 14, 168-179.	0.3	0
503	Pharmacology of Sudden Cardiac Death. , 0, , 203-219.		0
504	Recording Monophasic Action Potentials. , 2005, , 417-431.		0

#	ARTICLE	IF	CITATIONS
505	â€œZooming inâ€ to new horizons: Conduction abnormalities and other research perspectives in atrial fibrillation. <i>Heart Rhythm</i> , 2009, 6, 1118-1119.	0.3	0
506	Cell-based therapy of the failing heart: a need to connect for proper electrical and contractile function. <i>Europace</i> , 2010, 12, 1520-1521.	0.7	0
507	Does omega-3 fatty acid supplementation prevent atrial fibrillation, and if so, which type?. <i>Heart Rhythm</i> , 2011, 8, 569-570.	0.3	0
508	A real-time tip manometer for radiofrequency catheter ablation: new toy or useful tool?. <i>Europace</i> , 2011, 13, 159-160.	0.7	0
509	The European Network for Translational Research in Atrial Fibrillation. <i>Clinical Investigation</i> , 2012, 2, 1061-1067.	0.0	0
510	Antiarrhythmic drug treatment after cardioversion of atrial fibrillation â€“ Authors' reply. <i>Lancet</i> , The, 2012, 380, 1468.	6.3	0
511	'Patient choice' concept in AF ESC Guidelines: is the clinician giving up? Reply. <i>Europace</i> , 2013, 15, 460-461.	0.7	0
512	Questionable levels of evidence in new atrial fibrillation guidelines? Reply. <i>Europace</i> , 2013, 15, 461-462.	0.7	0
513	191â€...Advancement of Optical Mapping through Automated Algorithms and Second Generation CMOS Detectors to Reveal Murine Atrial Activation Patterns and Regional Variation of Action Potential Duration. <i>Heart</i> , 2014, 100, A106.1-A106.	1.2	0
514	Heartbeat: Highlights from the issue. <i>Heart</i> , 2014, 100, 817-818.	1.2	0
515	New Antiarrhythmic Drugs and New Concepts for Old Drugs. , 2014, , 1111-1119.		0
516	199â€...Pitx2c Deficiency May Increase the Antiarrhythmic Properties of Flecainide. <i>Heart</i> , 2014, 100, A109.2-A110.	1.2	0
517	YIA5â€...Plakoglobin Deficiency Leads to Increased Biventricular Beta-Catenin Expression in the Murine Heart. <i>Heart</i> , 2015, 101, A124.1-A124.	1.2	0
518	YIA3â€...Regional Action Potential Gradients in the Murine Left Atrium. <i>Heart</i> , 2015, 101, A123.1-A123.	1.2	0
519	The state of oral anticoagulant therapy in patients with atrial fibrillation in Spain. <i>Revista Clinica Espanola</i> , 2015, 215, 100-101.	0.2	0
520	168â€...Atrial arrhythmias and electrical remodelling after endurance training in a mouse model of arrhythmogenic right ventricular cardiomyopathy. <i>Heart</i> , 2015, 101, A95.2-A96.	1.2	0
521	170â€...Plakoglobin Deficiency Predisposes to Left Atrial Electrical Remodeling Following Chronic Exposure to Anabolic Steroids. <i>Heart</i> , 2016, 102, A119-A119.	1.2	0
522	217â€...Differences in Blood Biomarker Composition Between Paroxysmal AF and Sinus Rhythm Patients, Without Heart Failure. <i>Heart</i> , 2016, 102, A143.2-A144.	1.2	0

#	ARTICLE	IF	CITATIONS
523	44â€¦Diagnostic yield of 7-day holter ecg monitoring for new af and association with comorbidities. outcomes in an all-comer cohort from a large teaching trust. Heart, 2017, 103, A35-A36.	1.2	0
524	188â€¦Development of a novel software package for high-throughput processing and analysis of cardiac optical mapping data. Heart, 2017, 103, A128.2-A129.	1.2	0
525	221â€¦Altered biophysical properties of the voltage-gated sodium channels in mouse atrial and ventricular cardiomyocytes. Heart, 2017, 103, A143.3-A144.	1.2	0
526	Innovations in Antiarrhythmic Drug Therapy. , 2018, , 1076-1083.		0
527	151â€¦Direct evidence that sympathetic nervous activation accelerates ventricular conduction velocity, but inhibition of responses by DI-8-ANEPPS. , 2018, , .		0
528	133â€¦Langendorff-free method for isolation of cardiomyocytes from the adult and neonatal mouse hearts. , 2018, , .		0
529	128â€¦Desmosomal instability increases atrial arrhythmia susceptibility after endurance training. , 2018, , .		0
530	135â€¦Development and validation of high-throughput processing and analysis software platform for cardiac optical mapping. , 2018, , .		0
531	Reply. Journal of the American College of Cardiology, 2018, 72, 2546-2547.	1.2	0
532	Education as a vehicle towards quality improvement in the European Society of Cardiology. Cardiovascular Research, 2019, 115, e80-e81.	1.8	0
533	10â€¦A simple method to improve the reliability of echocardiography in patients with atrial fibrillation. , 2019, , .		0
534	23â€¦Predicting left ventricular dysfunction in a community-based cohort presenting to hospital using clinical characteristics, ECG parameters and biomarkers. , 2019, , .		0
535	Electrical cardioversion of atrial fibrillation and atrial flutter: manoeuvres and tips to increase its effectivenessâ€”Authorsâ€™ Reply. Europace, 2020, 22, 1602-1602.	0.7	0
536	Reduced Sodium Currents and Increased Sensitivity to Flecainide in Atrial Cardiomyocytes, Compared to Ventricular. Biophysical Journal, 2020, 118, 577a.	0.2	0
537	A Novel Biomarker Model for Detecting Patients With Atrial Fibrillation: A Development and Validation Study. SSRN Electronic Journal, 0, , .	0.4	0
538	Thrombus or No Thrombus. Journal of the American College of Cardiology, 2021, 77, 2887-2889.	1.2	0
539	Taking the heavy load off arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm, 2021, 18, 1192-1193.	0.3	0
540	OCEAN Trial Update. American Heart Journal, 2021, , .	1.2	0

#	ARTICLE	IF	CITATIONS
541	Reply to the Editorâ€™From AFFIRM to EASTâ€™Better rhythm control and general AF management explain differences in outcomes. Heart Rhythm, 2021, 18, 1814.	0.3	0
542	Connecting the dots? Rate control, heart failure, and atrial fibrillation. Cardiovascular Research, 2021, 117, 336-337.	1.8	0
543	The Heart and Brain Imaging in Lone Atrial Fibrillation â€œ Are We Surprised?. Current Pharmaceutical Design, 2014, 21, 613-621.	0.9	0
544	169â€™PITX2C deficiency augments the anti-arrhythmic properties of flecainide: results in a mouse model and validation in a human atrium simulation study. Heart, 2015, 101, A96.1-A96.	1.2	0
545	Almanac 2015: atrial fibrillation research in Heart. Cardiologia Croatica, 2016, 11, 162-175.	0.0	0
546	101â€™Differential effectors of the atrial resting membrane potential on the sodium channel blocking efficacy of propafenone and dronedarone. , 2018, , .		0
547	Influence of severe anemia on procedural safety and one-year outcome after left atrial appendage closure: Insights from a very high-risk cohort. IJC Heart and Vasculature, 2022, 38, 100946.	0.6	0
548	SupraventrikulÄre Tachykardien: In der Regel gutartig. , 0, , .		0
549	Vorhofflimmern: Medikamente oder Ablation. , 0, , .		0
550	Simultaneous Whole-Chamber Non-contact Mapping of Highest Dominant Frequency Sites During Persistent Atrial Fibrillation: A Prospective Ablation Study. Frontiers in Physiology, 2022, 13, 826449.	1.3	0
551	PO-699-05 ATRIAL ENDOMYSIAL FIBROSIS IS ASSOCIATED WITH SEX, ATRIAL FIBRILLATION, HEART FAILURE AND AGE IN CARDIAC SURGERY PATIENTS: RESULTS FROM THE CATCH ME CONSORTIUM. Heart Rhythm, 2022, 19, S430-S431.	0.3	0
552	Levels and Dynamics of estimated Glomerular Filtration Rate and Recurrent Vascular Events and Death in Patients with Minor Stroke or <scp>TIA</scp>. European Journal of Neurology, 0, , .	1.7	0
553	Prognostic markers of all-cause mortality in patients with atrial fibrillation: data from the prospective long-term registry of the German Atrial Fibrillation NETwork (AFNET): Authors' reply. Europace, 0, , .	0.7	0